

## **Solos Endoscopy Further Reduces its Outstanding Convertible Preferred Stock**

WESTPORT, CT, October 25, 2018 /PRNewswire/ -- Solos Endoscopy, Inc. (OTCPK: SNDY), a provider of quality medical devices to hospitals and clinics across the country, said it has completed another stage in the restructuring of its capitalization.

Dom Gatto, the Company's President and CEO, said that the Company has closed on its September 2018 agreements with two shareholders and purchased all of the Company's convertible securities which they owned: An aggregate of 64,613 shares of the Company's Series B Convertible Preferred Stock ("Series B") and \$15,000 principal amount of the Company's Convertible Promissory Notes issued by the Company's previous management.

The aggregate purchase price was \$80,000, which the Company paid by delivering to each seller a new Convertible Promissory Note in the principal amount of \$40,000, which amount will be offset by the net proceeds received by the holder from future sales of the shares of the Company's Common Stock that it currently owns. If a Note has not been paid in full after maturity, it will be convertible at a 50% discount to the market price of the Company's Common Stock; and the Company has reserved 8,000,000 shares of its Common Stock in the event of the conversion of each Note. One Note is due on September 27, 2019 and the other on March 4, 2020; and each bears interest at the rate of one and one-half percent (1.5%) per annum.

After giving effect to these transactions, all but 16,500 Series B shares are beneficially owned by Mr. Gatto. (These 16,500 Series B shares are pledged as collateral for the payment of a \$330,000 promissory note due to the Company from its former President.)

Mr. Gatto added: "Now, the Company can look to expand its management team with individuals with hands-on industry experience and proven leadership."

### **About Solos Endoscopy, Inc.:**

Additional information on the Company can be found on its website at:

[www.solosendoscopy.com](http://www.solosendoscopy.com).

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Annual Report filing and other filings with the OTC Markets Group (available at [www.otcm Markets.com](http://www.otcm Markets.com)). The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.

Solos Endoscopy, Inc.  
Investor Relations  
(617) 360-9700